BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 32401166)

  • 1. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
    Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
    Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
    Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R
    Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells.
    Liu L; Liu S; Luo H; Chen C; Zhang X; He L; Tu G
    Aging (Albany NY); 2021 Jun; 13(12):16178-16197. PubMed ID: 34182538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K; Thu N; Saville B; Safe S
    Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
    Li Y; Birnbaumer L; Teng CT
    Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Destabilization of microrchidia family CW-type zinc finger 2 via the cyclin-dependent kinase 1-chaperone-mediated autophagy pathway promotes mitotic arrest and enhances cancer cellular sensitivity to microtubule-targeting agents.
    Hu SY; Qian JX; Yang SY; Andriani L; Liao L; Deng L; Huang MY; Zhang YL; Zhang FL; Shao ZM; Li DQ
    Clin Transl Med; 2023 Mar; 13(3):e1210. PubMed ID: 36967563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.
    Cook KL; Clarke PA; Parmar J; Hu R; Schwartz-Roberts JL; Abu-Asab M; Wärri A; Baumann WT; Clarke R
    FASEB J; 2014 Sep; 28(9):3891-905. PubMed ID: 24858277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
    Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
    Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
    Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
    Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
    Chen Y; Li Z; He Y; Shang D; Pan J; Wang H; Chen H; Zhu Z; Wan L; Wang X
    Toxicol Appl Pharmacol; 2014 Mar; 275(2):176-81. PubMed ID: 24440569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
    Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA
    Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
    Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
    Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
    Hosford SR; Shee K; Wells JD; Traphagen NA; Fields JL; Hampsch RA; Kettenbach AN; Demidenko E; Miller TW
    Mol Oncol; 2019 Aug; 13(8):1778-1794. PubMed ID: 31180176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.